Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BKCa channels: Implications for soluble epoxide hydrolase inhibition

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 2, 2006, Pages

  Larsen, Brandon T ^a   Miura, Hiroto ^a   Hatoum, Ossama A ^a   Campbell, William B ^a   Hammock, Bruce D ^c   Zeldin, Darryl C ^d   Falck, John R ^e   Gutterman, David D ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cytochrome P 450 epoxygenase; Endothelium; Endothelium derived hyperpolarizing factor; Soluble epoxide hydrolase

Indexed keywords

1 CYCLOHEXYL 3 DODECYLUREA; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOCHROME P450; DIHYDROXYICOSATRIENOIC ACID; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; IBERIOTOXIN; ICOSATRIENOIC ACID; UNCLASSIFIED DRUG; UREA DERIVATIVE; CYP2C8 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; ICOSANOID; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; UNSPECIFIC MONOOXYGENASE; VASODILATOR AGENT;

ADULT; AGED; ARTERIOLE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; CHEMISTRY; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SOLUBILITY; VASODILATATION;

AGED; ARTERIOLES; ARYL HYDROCARBON HYDROXYLASES; CORONARY VESSELS; EICOSANOIDS; EPOXIDE HYDROLASES; FEMALE; HUMANS; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MIDDLE AGED; SOLUBILITY; VASODILATION; VASODILATOR AGENTS;

EID: 33644849675     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00927.2005     Document Type: Article

References (53)

1. Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, Platonov M, Koshal A, Hashimoto K, Campbell WB, Falck JR, and Michelakis ED. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK (Ca) channels. Circulation 107: 769-776, 2003.
2. + channels in NO- and hypoxia-induced pial artery vasodilation. Am J Physiol Heart Circ Physiol 272: H1785-H1790, 1997.
3. + channel on pig coronary artery endothelial cells. J Physiol 504: 537-543, 1997.
4. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, and Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 23: 374-380, 2002.
5. Campbell WB, Falck JR, and Gauthier K. Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary arteries. Med Sci Monit 7: 578-584, 2001.
6. Campbell WB and Gauthier KM. What is new in endothelium-derived hyperpolarizing factors? Curr Opin Nephrol Hypertens 11: 177-183, 2002.
7. Campbell WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
8. Daikh BE, Lasker JM, Raucy JL, and Koop DR. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 271: 1427-1433, 1994.
9. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, and Weiss RH. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 99: 2222-2227, 2002.
10. Enayetallah AE, French RA, Thibodeau MS, and Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 52: 447-454, 2004.
11. Fang X, Kaduce TL, Weintraub NL, and Spector AA. Cytochrome P450 metabolites of arachidonic acid: rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells. Prostaglandins Leukot Essent Fatty Acids 57: 367-371, 1997.
12. Fang X, Kaduce TL, Weintraub NL, VanRollins M, and Spector AA. Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 79: 784-793, 1996.
13. Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, Rice JB, Hammock BD, and Spector AA. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol 287: H2412-H2420, 2004.
14. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999.
15. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE, and Liggett WF. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261: 15334-15338, 1986.
16. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51, 2001.
17. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, and Campbell WB. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90: 1028-1036, 2002.
18. Gauthier KM, Edwards EM, Falck JR, Reddy DS, and Campbell WB. 14,15-Epoxyeicosatrienoic acid represents a transferable endothelium-dependent relaxing factor in bovine coronary arteries. Hypertension 45: 666-671, 2005.
19. Gebremedhin D, Harder DR, Pratt PF, and Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: role of a cytochrome P450 metabolite. J Vasc Res 35: 274-284, 1998.
20. Hecker M, Bara AT, Bauersachs J, and Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 481: 407-414, 1994.
21. 2+ entry in porcine aortic endothelial cells. Br J Pharmacol 121: 1579-1588, 1997.
22. Huang A, Sun D, Carroll MA, Jiang H, Smith CJ, Connetta JA, Falck JR, Shesely EG, Koller A, and Kaley G. EDHF mediates flow-induced dilation in skeletal muscle arterioles of female eNOS-KO mice. Am J Physiol Heart Circ Physiol 280: H2462-H2469, 2001.
23. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690-694, 2002.
24. Kaw S and Hecker M. Endothelium-derived hyperpolarizing factor, but not nitric oxide or prostacyclin release, is resistant to menadione-induced oxidative stress in the bovine coronary artery. Naunyn Schmiedebergs Arch Pharmacol 359: 133-139, 1999.
25. Krotz F, Riexinger T, Buerkle MA, Nithipatikom K, Gloe T, Sohn HY, Campbell WB, and Pohl U. Membrane potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 24: 595-600, 2004.
26. + channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 80: 877-884, 1997.
27. 2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ Res 93: 573-580, 2003.
28. Matoba T, Shimokawa H, Morikawa K, Kubota H, Kunihiro I, Urakami-Harasawa L, Mukai Y, Hirakawa Y, Akaike T, and Takeshita A. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler Thromb Vasc Biol 23: 1224-1230, 2003.
29. Miller FJ Jr, Dellsperger KC, and Gutterman DD. Pharmacologic activation of the human coronary microcirculation in vitro: endothelium-dependent dilation and differential responses to acetylcholine. Cardiovasc Res 38: 744-750, 1998.
30. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, and Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res 92: e31-e40, 2003.
31. + channels. Circ Res 83: 501-507, 1998.
32. + channels. Circulation 99: 3132-3138, 1999.
33. + channels. Circulation 103: 1992-1998, 2001.
34. Miura H, Wachtel RE, Loberiza FR Jr, Saito T, Miura M, Nicolosi AC, and Gutterman DD. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res 92: 151-158, 2003.
35. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, and Hammock BD. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63: 1599-1608, 2002.
36. Morisseau C and Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45: 311-333, 2005.
37. Nithipatikom K, Grall AJ, Holmes BB, Harder DR, Falck JR, and Campbell WB. Liquid chromatographic-electrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem 298: 327-336, 2001.
38. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999.
39. Oltman CL, Weintraub NL, VanRollins M, and Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 83: 932-939, 1998.
40. Pinto A, Abraham NG, and Mullane KM. Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther 240: 856-863, 1987.
41. Popp R, Brandes RP, Ott G, Busse R, and Fleming I. Dynamic modulation of interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic acid. Circ Res 90: 800-806, 2002.
42. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002.
43. Scarborough PE, Ma J, Qu W, and Zeldin DC. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev 31: 205-234, 1999.
44. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, and Takeshita A. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 28: 703-711, 1996.
45. Spiecker M and Liao JK. Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids. Arch Biochem Biophys 433: 413-420, 2005.
46. Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, and Liao JK. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 90: 1020-1027, 2002.
47. + channels. Am J Physiol Heart Circ Physiol 279: H2620-H2626, 2000.
48. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, and Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 100: 2793-2799, 1997.
49. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468, 1996.
50. Yang W, Gauthier KM, Reddy LM, Sangras B, Sharma KK, Nithipatikom K, Falck JR, and Campbell WB. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension 45: 681-686, 2005.
51. Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, and Weiss RH. Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol 286: F720-F726, 2004.
52. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062, 2001.
53. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, and Imig JD. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15: 1244-1253, 2004.